| AE-COPD (n = 30) | ARDS (n = 24) |
---|---|---|
Age (years) | 66 (61–72) | 66 (63–77) |
Male: n (%) | 12 (40%) | 17 (71%) |
FEV1 (L) | 0.97 (0.69–1.2) | NA |
FEV1 (%) | 35% (29.5–53) | NA |
PaO2/FiO2 (mmHg) | NA | 131 (100–190) |
SAPS II: | 36 (32–50) | 48 (43–62) |
Use of vasopressors: n (%) | 10 (33%) | 14 (58%) |
Type of ventilatory support | ||
 IMV: n (%) | 21 (70%) | 24 (100%) |
 NIV: n (%) | 9 (30%) | NA |
IMV settings before ECCO2R: | ||
 VT (ml/kg PBW) | 8.0 (7.8–8.1) | 5.9 (5.5–6.0) |
 Applied PEEP (cmH2O) | 0 (0–0) | 10 (5–15.5) |
 FiO2 (%) | 35 (30–38) | 60 (50–70) |
Measured parameters under IMV before ECCO2R: | ||
 Plateau pressure (cmH2O) | NA | 28 (27–29) |
 Total PEEP (cmH2O) | 9 (7–11) | NA |
 pH | 7.30 (7.25–7.32) | 7.24 |
 PaCO2 (mmHg) | 67.5 (60.75–73.25) | 58.0 (48.0–65.0) |
ECCO2R device | ||
 iLa Activve: n (%) | 5 (17%) | 6 (25%) |
 Hemolung: n (%) | 25 (83%) | 18 (75%) |
IMV settings and measured parameters at day 1 after starting ECCO2R: | ||
 VT (ml/kg PBW) | 7.98 (7.70–8.10) | 4.1 (3.9–4.8)* |
 pH | 7.39 (7.26–7.42)* | 7.31 (7.24–7.36)** |
 PaCO2 (mmHg) | 51.0 (45.5–56.0)* | 51.0 (44.5–55.7) |
ECCO2R duration (days): | 6.5 (3.25–8) | 4 (2–6) |
IMV duration (days) | 10 (4.75–15.25) | 8.5 (5.5–14.25) |
Course of ventilator support | ||
 IMV weaning success (IMV patients) | 16 (76%) | 7 (29%) |
 Intubation (NIV patients) | 1 (11%) | NA |
Mortality: n (%) | 10 (31%) | 17 (71%) |
 Linked to ECCO2R | 2 (7%) | 1 (4%) |